Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 1/20 | 0.37 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 2/20 | 0.32 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15702033 | 0.92 | ITGA4 (0.38) | ITGA4ITGB7CYP1A2CYP2D6ADORA1 | |
| SCHEMBL25336642 | 0.89 | LDHA (0.36) | ITGA4ITGB7CTSSCTSKATM | |
| SCHEMBL25336645 | 0.89 | LDHA (0.36) | ITGA4ITGB7CTSSCTSKATM | |
| SCHEMBL25338410 | 0.84 | CSK (0.39) | ITGA4ITGB7ADORA1POLBMAPT | |
| SCHEMBL25338406 | 0.84 | CSK (0.39) | ITGA4ITGB7ADORA1POLBMAPT | |
| SCHEMBL25528807 | 0.82 | MTNR1A (0.33) | ITGA4ITGB7 | |
| SCHEMBL6992860 | 0.80 | ADORA1 (0.41) | ITGA4ITGB7CYP1A2CYP2D6ADORA1 | |
| SCHEMBL6317673 | 0.80 | MMP13 (0.39) | ITGA4ADORA1 | |
| SCHEMBL1325198 | 0.80 | MMP13 (0.39) | ITGA4ADORA1 | |
| SCHEMBL1325201 | 0.80 | MMP13 (0.39) | ITGA4ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612421-B2 | Method for producing 4-borono-L-phenylalanine and intermediate thereof | STELLA PHARMA CORPORATION (JP) | 2026-04-28 | — | — | US | disclosed |
| US-20230416280-A1 | METHOD FOR PRODUCING 4-BORONO-L-PHENYLALANINE AND INTERMEDIATE THEREOF | STELLA PHARMA CORPORATION (JP) | 2023-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416280-A1 | METHOD FOR PRODUCING 4-BORONO-L-PHENYLALANINE AND INTERMEDIATE THEREOF | PAH, BCAT2, BCAT1 | ITGA4 4164/4885ITGB7 3202/4885CYP1A2 197/4885 |
| US-12612421-B2 | Method for producing 4-borono-L-phenylalanine and intermediate thereof | BCAT2, BCAT1, CLIC4 | ITGA4 2860/4885ITGB7 3636/4885CYP1A2 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.